JP Morgan Chase’s Pharvaris PHVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$546K Sell
20,005
-1,937
-9% -$51.7K ﹤0.01% 4932
2025
Q4
$609K Sell
21,942
-5,143
-19% -$124K ﹤0.01% 4901
2025
Q3
$676K Buy
27,085
+23,743
+710% +$527K ﹤0.01% 4849
2025
Q2
$58.8K Buy
3,342
+783
+31% +$12.6K ﹤0.01% 5852
2025
Q1
$40.2K Sell
2,559
-541
-17% -$9.12K ﹤0.01% 5957
2024
Q4
$59.4K Buy
3,100
+2,847
+1,125% +$58.6K ﹤0.01% 5951
2024
Q3
$4.69K Buy
+253
New +$4.62K ﹤0.01% 6501
2024
Q2
Sell
-3,150
Closed -$72.8K 7663
2024
Q1
$72.8K Buy
3,150
+2,960
+1,558% +$78.6K ﹤0.01% 5794
2023
Q4
$5.33K Buy
+190
New +$3.85K ﹤0.01% 6542
2023
Q3
Sell
-151
Closed -$2.37K 7657
2023
Q2
$2.37K Buy
+151
New +$1.46K ﹤0.01% 6307
2022
Q2
Sell
-3,429
Closed -$64K 6772
2022
Q1
$64K Sell
3,429
-13,535
-80% -$239K ﹤0.01% 5699
2021
Q4
$268K Buy
16,964
+1,060
+7% +$16.5K ﹤0.01% 5186
2021
Q3
$274K Sell
15,904
-530
-3% -$9.07K ﹤0.01% 5066
2021
Q2
$299K Buy
16,434
+2,560
+18% +$58.1K ﹤0.01% 5017
2021
Q1
$389K Buy
+13,874
New +$436K ﹤0.01% 4833

Other funds holding PHVS

JP Morgan Chase's PHVS Position: Q1 2026 in Review

JP Morgan Chase reduced its Pharvaris (PHVS) stake by 8.8% in Q1 2026, selling an estimated $51.7K and leaving 20,005 shares worth $546K. The position accounts for ﹤0.01% of the portfolio, ranked #4932.

JP Morgan Chase first reported a position in PHVS in Q1 2021 and has held it in 15 quarters since. The position peaked at $676K in Q3 2025. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

  • JP Morgan Chase held 20,005 shares of Pharvaris worth $546K as of Q1 2026.
  • JP Morgan Chase sold 1,937 Pharvaris shares in Q1 2026, an estimated $51.7K.
  • Pharvaris made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4932 holding.
  • JP Morgan Chase first reported a position in Pharvaris in Q1 2021 and has held it in 15 quarters since.
  • JP Morgan Chase's Pharvaris position peaked at $676K in Q3 2025.
  • 110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.